{"id":"taclonex-ointment-and-hydrogel-patch","safety":{"commonSideEffects":[{"rate":null,"effect":"Skin irritation or burning at application site"},{"rate":null,"effect":"Pruritus"},{"rate":null,"effect":"Skin atrophy (with prolonged use)"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":{"chemblId":"CHEMBL2108523","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calcipotriene acts as a vitamin D receptor agonist that promotes keratinocyte differentiation and reduces proliferation, while betamethasone dipropionate provides potent anti-inflammatory effects through glucocorticoid receptor activation. Together, these agents work synergistically to reduce erythema, scaling, and plaque formation characteristic of psoriasis. The ointment and hydrogel patch formulations provide different delivery mechanisms for topical application.","oneSentence":"Taclonex combines calcipotriene (vitamin D analog) and betamethasone dipropionate (corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:10:41.955Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis (topical treatment)"}]},"trialDetails":[{"nctId":"NCT00924950","phase":"PHASE4","title":"Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2009-06","conditions":"Plaque Psoriasis, Psoriasis Vulgaris","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Taclonex Ointment and Hydrogel Patch","genericName":"Taclonex Ointment and Hydrogel Patch","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Taclonex combines calcipotriene (vitamin D analog) and betamethasone dipropionate (corticosteroid) to reduce inflammation and normalize skin cell differentiation in psoriasis. Used for Plaque psoriasis (topical treatment).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}